In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia

Author:

Sahasrabudhe Deepak M.1,Liesveld Jane L.1,Minhajuddin Mohammad2,Singh Niloy A.1,Nath Subhangi3,Kumar Vishuwes M.3,Balys Marlene1,Evans Andrew G.1,Azadniv Mitra1,Hansen Jeanne N.4,Becker Michael W.1,Sharon Ashoke3,Thomas V Kaye5,Moore Richard G.1,Khera Manoj K.6,Jordan Craig T.2,Singh Rakesh K.1

Affiliation:

1. University of Rochester Medical Center

2. University of Colorado Anschutz Medical Campus

3. Birla Institute of Technology

4. Colgate University

5. University of Rochester

6. Presude Lifesciences Pvt Ltd

Abstract

AbstractAcute myeloid leukemia (AML) is fatal in majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that immunization of rabbits with normal peripheral WBCs that had been incubated with fluorodinitrobenzene elicited high titer antibodies that bound to a spectrum of human leukemias. We report that proteomic analyses of immunoaffinity-purified lysates of primary AML cells showed enrichment of scaffolding protein IQGAP1. Immunohistochemistry and gene-expression analyses confirmed IQGAP1 mRNA overexpression in various cytogenetic subtypes of primary human AML compared to normal hematopoietic cells. shRNA knockdown of IQGAP1 blocked proliferation and clonogenicity of human leukemia cell-lines. To develop small molecules targeting IQGAP1 we performedin-silicoscreening of 212,966 compounds, selected 4 hits targeting IQGAP1-GRD domain, and conducted SAR of ‘fittest hit’ to identify UR778Br, a prototypical agent targeting IQGAP1. UR778Br inhibited proliferation, induced apoptosis, G2/M arrest, and colony formation by leukemia cell-lines and primary-AML while sparing normal marrow cells. IQGAP1/F-actin showed co-localization and UR778Br induced filopodia formation in U937 cells. UR778Br exhibited favorable ADME/T profiles and drug-likeness to treat AML. In summary, AML shows dependency on IQGAP1 and UR778Br, identified throughin-silicostudies, selectively targeted AML cells while sparing normal marrow.

Publisher

Research Square Platform LLC

Reference63 articles.

1. Acute myeloid leukemia;Döhner H;N. Eng. J. of Med.,2015

2. Segel, R., Miller, K., Fuchs H and Jemal A. Cancer Statistics, CA: A Journal for Clinicians 71, 7–33 (2021).

3. Current management of childhood acute myeloid leukemia;Rubnitz JE;Paed. Drugs,2017

4. Patterns of care and survival for elderly acute myeloid leukemia-challenges and opportunities;Mangaonkar AA;Curr. Hematol. Malig. Rep,2017

5. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry;Juliusson G;Blood,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3